Drugs / Samotolisib
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02784795 | Nov 2016 → Aug 2018 | breast cancer, cholangiocarcinoma, colon carcinoma, soft tissue sarcoma | Eli Lilly and Company | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02818335 | Jul → Oct 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02575703 | Oct → Nov 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02536586 | Sep 2015 → Feb 2017 | neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02124148 | Jun 2014 → Feb 2020 | breast cancer, colorectal neoplasm, metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02079636 | Mar 2014 → May 2018 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02057133 | Mar 2014 → Mar 2021 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01655225 | Jul 2012 → Apr 2019 | breast cancer, cancer of unknown primary site, malignant mesothelioma, metastatic malignant neoplasm +2 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 28 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04032080 | Sep 2019 → Jun 2022 | triple-negative breast carcinoma | Baylor Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03675893 | Dec 2018 → Aug 2028 expected | endometrial cancer | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT03213678 | Nov 2017 → Sep 2023 | Ewing sarcoma, Langerhans cell histiocytosis, Wilms tumor, ependymoma +11 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03155620 | Jul 2017 → Mar 2025 overdue | Ewing sarcoma, Langerhans cell histiocytosis, Wilms tumor, conventional osteosarcoma +13 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02981342 | Jan 2017 → Apr 2018 | pancreatic ductal adenocarcinoma | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT02549989 | Sep 2015 → Mar 2022 | endometrial cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02443337 | Jul 2015 → Sep 2017 | non-small cell lung carcinoma | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT02407054 | Apr 2015 → Sep 2018 | metastatic prostate carcinoma | Eli Lilly and Company | Completed | Met primary |
| Phase not stated1 trial | ||||||
| — | NCT02632994 | — | cancer | Eli Lilly and Company | Available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Samotolisib | “PURPOSE: To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with...” PMID 35363301 ↗ Jun 2022 |
| Known as | LY3023414 | “PURPOSE: To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with...” PMID 35363301 ↗ Jun 2022 |
| Action | Inhibit | “selective, ATP competitive inhibitor of class I PI3K isoforms, mTORC1/2 and DNA-PK” PMID 33660194 ↗ Mar 2021 |
| Modality | Small molecule | — CHEMBL4297181 ↗ |
| Route | Oral | “Administered orally. Dose of 20 to 600 mg, as determined in Part A.” NCT01655225 ↗ |
| Target | MTOR | “PI3K/mTOR dual kinase” PMID 35363301 ↗ Jun 2022 |